We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+12.48%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.34B
AUM Growth
+$149M
(+6.8%)
Cap. Flow
+$32.9M
Cap. Flow
% of AUM
1.41%
Top 10 Holdings %
Top 10 Hldgs %
89.52%
Holding
38
New
10
Increased
4
Reduced
4
Closed
9
Top Buys
| 1 |
AKTS
Aktis Oncology
AKTS
|
+$93.7M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$73.8M |
| 3 |
CG Oncology
CGON
|
+$18.7M |
| 4 |
Relay Therapeutics
RLAY
|
+$17M |
| 5 |
Erasca
ERAS
|
+$10.6M |
Top Sells
| 1 |
Immunome
IMNM
|
+$61.3M |
| 2 |
MBX
MBX Biosciences
MBX
|
+$45.8M |
| 3 |
Structure Therapeutics
GPCR
|
+$23.3M |
| 4 |
Vaxcyte
PCVX
|
+$20.8M |
| 5 |
Aquestive Therapeutics
AQST
|
+$17M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Financials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zymeworks
ZYME
$1.82B
| $575M | 24.58% |
22,970,388
| – | – |
|
2
AnaptysBio
ANAB
$1.66B
| $437M | 18.68% |
7,880,094
| – | – |
|
3
Jazz Pharmaceuticals
JAZZ
$15.1B
| $323M | 13.79% |
1,706,469
| – | – |
|
|
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
| $238M | 10.18% |
6,000,000
+2,885,000
| +93% | +$73.8M |
|
5
Crinetics Pharmaceuticals
CRNX
$8.88B
| $156M | 6.66% |
4,288,120
| – | – |
|
|
AKTS
6
Aktis Oncology
AKTS
$1.38B
| $86.3M | 3.69% |
+4,824,469
| New | +$93.7M |
|
7
Oric Pharmaceuticals
ORIC
$1.11B
| $85.2M | 3.64% |
6,728,116
| – | – |
|
|
8
CG Oncology
CGON
$6.4B
| $74.6M | 3.19% |
1,102,000
+330,000
| +43% | +$18.7M |
|
9
CRISPR Therapeutics
CRSP
$4.97B
| $66.1M | 2.82% |
1,389,276
| – | – |
|
10
Eton Pharmaceutcials
ETON
$1.02B
| $53.6M | 2.29% |
2,171,938
+141,394
| +7% | +$2.47M |
|
|
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.95B
| $50M | 2.14% |
1,667,119
| – | – |
|
12
Xencor
XNCR
$1.1B
| $26.3M | 1.13% |
2,183,000
-1,068,112
| -33% | -$13.3M |
|
13
Neurogene
NGNE
$785M
| $25.6M | 1.1% |
1,271,342
| – | – |
|
|
BBOT
14
BridgeBio Oncology
BBOT
$683M
| $25.3M | 1.08% |
2,823,126
| – | – |
|
|
MBX
15
MBX Biosciences
MBX
$2.74B
| $23.2M | 0.99% |
777,000
-1,346,604
| -63% | -$45.8M |
|
|
16
Relay Therapeutics
RLAY
$4.15B
| $19M | 0.81% |
+1,904,762
| New | +$17M |
|
|
ZBIO
17
Zenas BioPharma
ZBIO
$1.75B
| $15.4M | 0.66% |
789,500
| – | – |
|
|
18
Erasca
ERAS
$6.25B
| $14.6M | 0.62% |
+900,000
| New | +$10.6M |
|
|
EIKN
19
Eikon Therapeutics
EIKN
$539M
| $7.75M | 0.33% |
+732,606
| New | +$9.79M |
|
20
Replimune Group
REPL
$808M
| $7.65M | 0.33% |
+1,000,000
| New | +$7.64M |
|
21
Zura Bio
ZURA
$486M
| $7.02M | 0.3% |
+1,179,715
| New | +$7.13M |
|
22
Phathom Pharmaceuticals
PHAT
$877M
| $6.94M | 0.3% |
+625,000
| New | +$7.89M |
|
|
MREO
23
Mereo BioPharma
MREO
$51.3M
| $4.41M | 0.19% |
13,368,855
+5,512,389
| +70% | +$2.37M |
|
24
Stoke Therapeutics
STOK
$1.82B
| $3.26M | 0.14% |
+100,000
| New | +$3.28M |
|
25
Prelude Therapeutics
PRLD
$346M
| $3.24M | 0.14% |
+947,049
| New | +$2.48M |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM